Company overview
NervGen Pharma is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics, primarily NVG-291, a peptide targeting spinal cord injury and other neurologic conditions. NVG-291 is in Phase 1b/2a trials, showing functional improvements in chronic spinal cord injury patients, with preclinical data supporting applications in peripheral nerve injury, hearing loss, and stroke. The company also advances NVG-300 in preclinical models for neurotraumatic conditions.
NervGen Pharma is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include nervgen pharma, nvg-291, spinal cord injury, neuroreparative therapeutics, clinical stage biotech.
Structured facts
- Website
- https://nervgen.com
- Markets served
- United States & Americas
- Keywords
- nervgen pharma, nvg-291, spinal cord injury, neuroreparative therapeutics, clinical stage biotech
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What is NervGen's lead product candidate?
- NVG-291, a first-in-class subcutaneously administered peptide that promotes nervous system repair by targeting chondroitin sulfate proteoglycans (CSPGs), currently in Phase 1b/2a trials for chronic spinal cord injury.
- What clinical trial data supports NVG-291?
- In the Phase 1b/2a CONNECT SCI Study, NVG-291 demonstrated increased function, independence, and quality of life in individuals with chronic spinal cord injury up to ten years post-injury.
- What are NervGen's therapeutic areas and preclinical pipeline?
- Focus on spinal cord injury, with preclinical evidence for NVG-291 in peripheral nerve injury, blast-induced hearing loss, stroke, and multiple sclerosis; NVG-300 is in preclinical development for neurotraumatic conditions.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
